Article Per Year (5 Year)
p-Index From 2021 - 2026
1.554
P-Index
This Author published in this journals
All Journal ISM (Intisari Sains Medis) : Jurnal Kedokteran Jurnal Respirasi (JR) Health and Medical Journal Respiratory Science Indonesian Journal of Cancer Journal of Global Pharma Technology
Ida Ayu Jasminarti Dwi Kusumawardani
Department Of Pulmonology And Respiratory Medicine, Medical Faculty Of Udayana University/Sanglah Hospital, Bali, Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Periorbital Necrotizing Fasciitis in Lung Adenocarcinoma Patient Receiving Afatinib: A Case Report Kusumawardani, Ida Ayu Jasminarti Dwi; Tan, Leviani; Indraswari, Putu Gita; Yuliawati, Putu; Wiradana, A.A. Gde Agung Anom Arie
Indonesian Journal of Cancer Vol 20, No 1 (2026): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i1.1417

Abstract

Background: Afatinib is a second-generation Tyrosine Kinase Inhibitor (TKI) approved by the Food and Drug Administration (FDA) as first-line therapy for advanced Non-small cell lung cancer (NSCLC) with distant organ metastasis. However, afatinib has been reported to cause several side effects. Here, we report a case of periorbital necrotizing fasciitis, potentially associated with afatinib use, presenting as a grade 3 side effect in a 59-year-old woman with stage IVB lung adenocarcinoma. This is the first literature reporting afatinib-related periorbital necrotizing fasciitis, a rare sight-threatening infection.Case Presentation: A 59-year-old female patient came to the Emergency Room with a protruding left eye, which is accompanied by redness, purulent discharge, and a blackish wound around the left eye area for the last 5 days. The patient had been diagnosed with stage IVB lung adenocarcinoma (T4N3M1c) six months ago. Previously, she underwent chemotherapy with a combination of Gemcitabine and Carboplatin. The patient then underwent 20 cycles of radiotherapy followed by immunotherapy using afatinib. The patient was then admitted with suspected necrotizing fasciitis of the left periorbital area due to side effects of afatinib. She was given ceftriaxone 2 grams every 24 hours intravenously (IV), analgesics IV, methylprednisolone IV, gentamicin eye drops, and regular wound care. After several days of treatment, the patient had significant improvement. Afatinib therapy was temporarily stopped. Re-evaluation at one month showed significant improvement in the patient's left periorbital area. Afatinib therapy was then continued at a lower dose of 30 mg every 24 hours.Conclusions: Good education and caution are still needed for patients who were given afatinib. More studies on the side effects of afatinib are needed to identify predisposing factors and establish a consensus on the management of afatinib-induced periorbital necrotizing fasciitis in NSCLC patients.
Co-Authors Ana Rima Setijadi Ananda, Fannie Rizki Duyen, Natalie Elisna Syahruddin Ermayanti, Sabrina Hanif, Muhammad Alfin Haryati Haryati Herman Saputra Herman Saputra I Gede Ketut Sajinadiyasa I Gusti Ayu Sri Mahendra Dwi Ida Bagus Ngurah Rai IGN Bagus Artana Infianto, Andreas Laksmi Wulandari Lim, Darren Wan-Teck Luh Komang Ayu Widhiaty Karang Ni Luh Gede Yoni Komalasari, Ni Luh Gede Yoni Ni Luh Putu Eka Arisanti Ni Made Ary Sarasmita Ni Putu Ayu Widiasari Ni Putu Ayu Widiasari Ni Putu Sriwidyani Ni Wayan Candrawati Noni Novisari Soeroso Nornazirah Binti Azizan Novita Andayani, Novita Pratama, Avissena Dutha Pratiwi, Suryanti Dwi Putri, Kadek Sri Adi Putu Gita Indraswari, Putu Gita Putu Yuliawati Raka-Sudewi A. A. Senja Decy Ningrum Sri Melati Munir Tan, Leviani Venny Singgih Victor Nugroho Wijaya Wayan Evie Frida Yustin Wiradana, A.A. Gde Agung Anom Arie Yuliawati, Putu